The introduction of lecanemab, a new infusion therapy for Alzheimer’s disease (AD), has unveiled stark disparities in access and adoption...

In a groundbreaking new study poised to reshape our understanding of metabolic interventions in neurodegenerative diseases, researchers have demonstrated that...

Parkinson’s disease (PD), a progressive neurodegenerative disorder marked by motor impairments and non-motor symptoms, has long posed a significant clinical...

In 2023, the Food and Drug Administration (FDA) rendered a groundbreaking decision by approving lecanemab, a novel therapeutic agent aimed...

MINNEAPOLIS — A compelling new study published online in the medical journal Neurology has uncovered a significant association between the...

In a landmark advancement in neurodegenerative disease therapeutics, researchers have unveiled promising results from a randomized, double-blind phase 1b clinical...

Could a simple retinal examination revolutionize the early diagnosis of Parkinson’s disease? This provocative possibility has gained substantial traction following...

In a groundbreaking development in neurodegenerative disease research, advances in positron emission tomography (PET) tracer technology are revolutionizing the diagnosis...

Parkinson’s disease, a relentless neurodegenerative disorder, has long challenged scientists and clinicians due to its complex pathology and elusive early...

In a groundbreaking advancement for Parkinson’s disease therapy, researchers have reported the results of a first-in-human Phase I/II clinical trial...